Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $10.00 Consensus Price Target from Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been assigned a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $10.00.

PYXS has been the subject of a number of research analyst reports. William Blair lowered Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 21st. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research note on Thursday, November 21st. Stephens assumed coverage on shares of Pyxis Oncology in a report on Friday, November 8th. They issued an “overweight” rating and a $13.00 price target on the stock. Finally, Royal Bank of Canada raised their price target on shares of Pyxis Oncology from $7.00 to $10.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st.

Insiders Place Their Bets

In related news, CFO Pamela Ann Connealy acquired 88,850 shares of the stock in a transaction on Tuesday, November 26th. The shares were bought at an average price of $1.96 per share, with a total value of $174,146.00. Following the completion of the purchase, the chief financial officer now owns 1,199,143 shares of the company’s stock, valued at approximately $2,350,320.28. This represents a 8.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 9.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Pyxis Oncology in the third quarter valued at about $1,405,000. Bank of New York Mellon Corp boosted its holdings in Pyxis Oncology by 92.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 311,630 shares of the company’s stock valued at $1,031,000 after purchasing an additional 149,522 shares during the last quarter. abrdn plc grew its stake in shares of Pyxis Oncology by 28.9% in the 3rd quarter. abrdn plc now owns 913,045 shares of the company’s stock valued at $3,351,000 after buying an additional 204,742 shares during the period. Millennium Management LLC increased its holdings in shares of Pyxis Oncology by 125.3% during the 2nd quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock worth $4,425,000 after buying an additional 743,499 shares during the last quarter. Finally, Blue Owl Capital Holdings LP purchased a new stake in shares of Pyxis Oncology during the 2nd quarter valued at approximately $3,462,000. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Trading Up 6.6 %

Shares of Pyxis Oncology stock opened at $1.62 on Friday. The firm’s 50 day simple moving average is $3.10 and its two-hundred day simple moving average is $3.37. The firm has a market capitalization of $96.34 million, a price-to-earnings ratio of -1.57 and a beta of 1.00. Pyxis Oncology has a 12-month low of $1.51 and a 12-month high of $6.85.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.